FDA approves Merilog (insulin-aspart-szjj) as the first rapid-acting insulin biosimilar to Novolog for glycemic control in adult and pediatric diabetes patients, expanding treatment accessibility.
Data from the phase III ReNeu trial showed the kinase inhibitor led to an overall response rate of 41% in adult patients and 52% in pediatric patients.
FDA-cleared clinical trials will assess the safety, immunogenicity, and viability of genetically modified pig kidney transplants in patients with end-stage renal disease.